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Table 1. Levels of pro- and anti-inflammatory factors, for different stages of pathology of hepatic fibrosis.
Cytokine
Stage 1
(n p 28)
P a
(stage 1
vs. stage 2)
Stage 2
(n p 10)
P a
(stage 2
vs. stage 3)
Stage 3
(n p 10)
sTNFR-1, pg/mL 683 (531–1550) .264 669 (489–998) .241 744 (532–2128)
sTNFR-2, pg/mL 2264 (1403–6781) .208 2748 (1709–7174) .031 1945 (1214–2953)
TNF-a, pg/mL 238 (0–921) .113 126 (0–471) .264 177 (22–2452)
sICAM-1, ng/mL 826 (62–2426) .281 738 (32–1739) .157 604 (356–1142)
IL-10, pg/mL 141 (0–2914) .339 140 (0–344) .017 359 (79–3162)
IFN-g, IU/mL 2.15 (0–6.2) .022 0 (0–5.4) .026 2 (0–10)
NOTE. Data are median (range) of values, unless otherwise indicated. IFN, interferon; IL, interleukin; sICAM, soluble intercellular
cell-adhesion molecule; sTNFR, soluble tumor necrosis factor receptor; TNF, tumor necrosis factor.
a (nonparametric Mann-Whitney test) was considered to be statistically significant; these values are in boldface type. AP ! .05
statistically significant difference ( ) also was found between stages 1 and 3, for both IL-10 and sICAM-1.Pp .031
Association between Serum
Cytokine Profiles
and Schistosomiasis-Related
Hepatic Fibrosis: Infection
by Schistosoma japonicum
versus S. mansoni
To the Editor—In the 1 August 2005 issue
of the Journal, Coutinho et al. described,
in patients infected by Schistosoma japo-
nicum, a correlation between the levels of
certain cytokines and the presence of he-
patic fibrosis (HF) [1]: they found that the
levels of both interleukin (IL)–1 and IL-6
were higher in patients with HF than in
patients without HF, and they also re-
ported that the presence of HF was neg-
atively correlated with body-mass index.
We found these results to be particularly
interesting, because we have noted a sim-
ilar correlation between HF and immu-
nological parameters.
We recently reported a relationship
between anti–soluble egg antigen (anti-
SEA)–isotype antibody responses and por-
tal hypertension (PH) in Schistosoma man-
soni–infected patients in Saint Louis,
Senegal [2]. This hyperendemic situation
is noteworthy in that the illness emerged
after a recent change in the ecosystem—
a dam was constructed on the Senegal
River in 1986, and the first cases of schis-
tosomiasis were diagnosed in 1988. The
disease was severe and rapidly progres-
sive, with the first cases of PH being ob-
served in 1994 [3].
Using hepatic sonography and gastric
fibroscopy, we have screened for HF in a
cohort of 142 S. mansoni–infected pa-
tients; patients with HF were classified as
belonging to 1 of 3 categories based 3
stages of pathology: (1) those who were
free of HF (no morbidity—i.e., clinical
and hepatic ultrasound findings were nor-
mal); (2) those in whom hepatic ultra-
sound findings were abnormal but in
whom gastric fibroscopy showed no signs
of PH (moderate morbidity); and (3)
those in whom gastric fibroscopy showed
esophageal varices (severe morbidity). We
found that the presence of PH—and,
therefore, of HF—correlated positively
with levels of anti-SEA IgG4, IgA, and IgE
[2]. We also measured serum levels of pro-
and anti-inflammatory factors—soluble
intercellular cell-adhesion molecule-1, sol-
uble tumor necrosis factor receptor-1 and
–2, interferon (IFN)–g, tumor necrosis
factor (TNF)–a, and IL–10—in the same
patients, to determine whether HF was as-
sociated with a particular inflammatory
profile. As shown in table 1, levels of IL-
10 were higher in patients with stage 3
disease than in patients with either stage
1 disease or stage 2 disease, whereas levels
of IFN-gwere lowest in patients with stage
2 disease.
This correlation between the clinical
stage of the disease and the serum level of
IL-10 was independent of age, sex, or se-
verity of infection (as determined on the
basis of S. mansoni egg counts in stool
samples). High levels of an anti-inflam-
matory cytokine, such as IL-10, during
the advanced stage of the disease may be
linked to PH itself. Indeed, inflamma-
tion triggered by PH could lead to the se-
cretion of anti-inflammatory cytokines,
and these elevated levels of IL-10 would
therefore reflect an attempt to dampen
the inflammatory reaction. Other studies
have also suggested a link between high
levels of IL-10 and the severity of para-
sitic infections; for example, Perkins et
al. [4] and Ho et al. [5] have reported
that severe malaria is associated with el-
evated levels of IL-10.
Our findings show that the inflamma-
tory balance is altered in S. mansoni–in-
fected patients who have advanced HF.
The differences between stages 2 (mod-
erate HF) and 3 (severe HF) of the disease
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could serve as a means by which to mon-
itor disease progression, without the need
for invasive examinations (e.g., gastric fi-
broscopy to detect esophageal varices).
Early detection of a change from a pro-
to an anti-inflammatory cytokine profile
could serve as a way to identify a high-
risk population of patients who require
closer clinical and biological monitoring.
In the same way that antibody responses
vary between stages 2 and 3 of the disease
[1], the inflammatory profile changes as
the disease progresses, suggesting that ad-
vanced stage of the disease are accompa-
nied by an accelerated immune reaction.
The concomitant increase in levels of IFN-
g during the later stage of the disease (i.e.,
stage 3 vs. stage 2) (table 1) implies the
presence of a mechanism of this type.
Finally, the fact that, despite the dif-
ference in the parasite species studied
(S. japonicum vs. S. mansoni), our re-
sults are similar to those of Coutinho
et al. suggests that there is a common
pathophysiological mechanism governing
the onset and regulation of HF in patients
with schistosomiasis.
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Reply to Bonnard et al.
To the Editor—It is indeed interesting
that, in their study in Senegal, Bonnard et
al. [1]found elevated serum levels of in-
terleukin (IL)–10 in patients with severe
morbidity due to chronic Schistosoma
mansoni infection—and that this finding
was independent of age, sex, or S. man-
soni egg count. These results are similar
to the findings that my colleagues and I
had reported in our article in the Journal
[2], despite the following differences in
the 2 studies’ populations and designs:
(1) in the study by Bonnard et al., par-
ticipants were recruited at a local health
center, whereas our study was commu-
nity based; (2) the age range in the study
by Bonnard et al. was 11–80 years, versus
7–30 years in our study; (3) current schis-
tosomiasis infection was not a require-
ment for participation in the study by
Bonnard et al. if pathology as detected
by ultrasonography or endoscopy was
present, whereas in our study it was a
requirement for all participants; and (4)
the 2 studies used different systems for
classification of hepatic fibrosis (HF).
It seems plausible that the immunoreg-
ulatory mechanism involved in the de-
velopment of HF is similar across species.
The idea of using noninvasive, immuno-
logic screening tools to facilitate the de-
tection of severe HF and/or associated
morbidity is interesting. However, a few
issues should be discussed in this regard.
First, there is no evidence for a “change
from a pro- to an anti-inflammatory cy-
tokine profile” during the development of
severe HF. On the contrary, as mentioned
by Bonnard et al., as well as in the Dis-
cussion section of our article [2], the in-
creased levels of serum IL-10 that are as-
sociated with severe HF likely reflect an
attempt to dampen increased levels of
proinflammatory cytokines. In line with
this hypothesis, we found that both the
level of IL-1 and the percentage of indi-
viduals with detectable levels of IL-6 were
increased in subjects with severe HF [2].
Other studies have found increased levels
of a proinflammatory cytokine, tumor ne-
crosis factor (TNF)–a, and its receptor,
soluble TNF receptor (sTNFR)–1, in in-
dividuals with severe hepatic morbidity
[2–5]. In contrast, Bonnard et al. found
decreased levels of sTNFR-2 in subjects
with severe morbidity—and, with pro-
gression of morbidity, a decrease, followed
by an increase, in levels of interferon
(IFN)–g.
Second, the determination of which
cutoff values for levels of IL-10 should
be used to discriminate between different
stages of hepatic morbidity may be dif-
ficult. Even if studies with large numbers
of individuals were used to determine
these cutoff values, coinfection with other
pathogens could interfere with their reli-
ability. Serum IL-10 is likely not specific
enough to qualify as a marker for schis-
tosomiasis-associated hepatic morbid-
ity. Levels of cytokines produced in re-
sponse to specific schistosome antigens
could be used instead, to overcome the
confounding effects of coinfection with
other pathogens; however, such an assay
is likely to be too expensive to have pub-
lic-health utility in the developing world.
Another issue concerns the possible in-
fluence of genetic polymorphisms in re-
lation to cytokine responses. Polymor-
phisms in the IFN-g receptor gene have
been found that may be responsible for
the susceptibility of certain individuals to
severe HF [6]. Several IL-10 receptor gene
polymorphisms may also be of biological
significance [7], but their role in the de-
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velopment of schistosomiasis-associated
HF is currently unknown. These poly-
morphisms could predispose to develop-
ment of HF, which would further limit the
suitability of serum IL-10 as a marker for
hepatic morbidity.
Finally, Bonnard et al. have described
other immunologic markers that are spe-
cific for schistosomiasis [8] and may be
more suitable as markers for disease
progression.
Hannah M. Coutinho
Center for International Health Research, Brown
University, Providence, Rhode Island
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